Combining a complement inhibitor with rituximab was found to rapidly control severe autoimmune hemolytic anemia (AIHA), including in two patients with cold agglutinin syndrome, a condition related to cold agglutinin disease. In two of the three patients in the series, the complement inhibitor Enjaymo (sutimlimab) was later…
News
Careful planning, warming measures, and close teamwork between medical specialists may allow for the safe collection and transplant of blood-forming stem cells in people with cold agglutinin disease (CAD) to rebuild a healthy bone marrow after high-dose chemotherapy. That’s according to a study reporting a successful procedure in a…
Certain types of blood cancer may increase the risk of cold agglutinin disease (CAD), and while the presence of both conditions has historically been associated with worse survival, a study suggests that modern, targeted cancer treatments have reduced this negative effect. Because newer therapies are generally more effective at…
Some people with a diagnosis of cold agglutinin disease (CAD) secondary to another condition — when it’s then known as cold agglutinin syndrome, or CAS — may actually just have CAD. That’s the hypothesis set forth in a small study, involving eight people with “clinically well-characterised CAD or CAS,”…
A stem cell transplant led to lasting remission of cold agglutinin disease (CAD) secondary to an aggressive lymphoma in a 48-year-old woman, according to a case report from Japan. This was only the second reported CAD case in which levels of disease-causing self-reactive antibodies completely normalized after a stem…
A 58-year-old woman who developed cold agglutinin disease (CAD) as a complication of blood cancer improved after treatment with medications to reduce the immune attack on red blood cells, along with chemotherapy for the underlying cancer. Meanwhile, corticosteroids and other medications helped two patients with different forms of autoimmune…
Gilead Sciences and Lakefront Biotherapeutics have acquired Ouro Medicines and its investigational therapy, gamgertamig, for cold agglutinin disease (CAD) and other forms of autoimmune hemolytic anemia (AIHA). Gamgertamig is also being developed as a treatment for several other autoimmune diseases. Under the deal, valued at up to $2.175 billion,…
A 70-year-old woman with cold agglutinin disease (CAD) avoided disease-related complications from surgery related to a heart condition, in part because she took Enjaymo (sutimlimab-jome) before the operation for a heart condition, a case study from the U.S. reported. In addition to giving the woman Enjaymo, an approved…
A woman with cold agglutinin disease (CAD) who was misdiagnosed with and treated for a blood cancer achieved lasting health improvements once doctors switched her to Enjaymo (sutimlimab-jome), a case study shows. The woman had initially received therapies for chronic lymphocytic leukemia (CLL). However, those treatments failed to…
A 78-year-old woman with cold agglutinin disease (CAD) was later found to have acute myeloid leukemia (AML), a type of blood cancer, which likely caused the disease, according to a case study from the U.S. Doctors discovered the woman’s AML after her anemia continued to worsen despite signs that…
Recent Posts
- Combination therapy brings durable remission in severe AIHA case series
- Like my beloved Auburn Tigers, I have a new approach to my treatment for CAD
- Walking backward on ice to treat my cold agglutinin disease
- 4 magical words that transformed an ordinary Monday into a good day
- Precautions support safe stem cell transplant in man with CAD